MIST241115P7500
- 0.00
- 0.000.00%
Milestone Pharmaceuticals Newsroom
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $9
Milestone Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $9
TD Cowen Sticks to Its Buy Rating for Milestone Pharmaceuticals (MIST)
Rodman & Renshaw Initiates Milestone Pharmaceuticals(MIST.US) With Buy Rating, Announces Target Price $9
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Milestone Pharmaceuticals: A Buy Rating on CARDAMYST's Market Potential and FDA Progress
Rodman & Renshaw Initiates Coverage On Milestone Pharmaceuticals With Buy Rating, Announces Price Target of $9
Milestone Pharmaceuticals Analyst Ratings
Piper Sandler Sticks to Their Buy Rating for Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Milestone Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Strong Buy Rating for Milestone Pharmaceuticals Amidst Promising CARDAMYST Prospects and Market Strategy
Milestone Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Milestone Pharmaceuticals' Strong Buy Rating: CARDAMYST's FDA Resubmission and Bright Revenue Prospects
Milestone Pharmaceuticals Analyst Ratings